Eads & Heald Wealth Management Biogen Inc. Transaction History

Eads & Heald Wealth Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$223.92 - $287.77 $170,403 - $218,992	-761 Closed	0 $0
Q3 2021 Oct 27, 2021	BUY	$282.99 - $369.05 $215,355 - $280,847	761 New	761 $215,000
Q1 2019 Apr 26, 2019	SELL	$216.71 - $338.96 $174,451 - $272,862	-805 Closed	0 $0
Q3 2018 Oct 31, 2018	SELL	$293.51 - $383.83 $8,805 - $11,514	-30 Reduced 3.59%	805 $0
Q2 2018 Jul 27, 2018	SELL	$257.52 - $306.91 $8,498 - $10,128	-33 Reduced 3.8%	835 $0
Q1 2018 Apr 26, 2018	BUY	$260.13 - $367.91 $20,290 - $28,696	78 Added 9.87%	868 $0
Q4 2017 Jan 31, 2018	SELL	$307.64 - $344.58 $27,687 - $31,012	-90 Reduced 10.23%	790 $0
Q3 2017 Oct 27, 2017	BUY	$281.15 - $329.69 $247,411 - $290,127	880	880 $0

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Eads & Heald Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Eads & Heald Wealth Management with notifications on news.